Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$129.73
+2.6%
$118.06
$5.63
$148.83
$10.34B0.841.10 million shs1.08 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$77.15
+1.1%
$68.04
$30.02
$80.20
$9.60B0.382.21 million shs1.62 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.71
+3.9%
$23.00
$12.97
$27.72
$11.84B1.695.41 million shs8.28 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$29.28
-0.2%
$30.80
$19.26
$39.28
$2.57B-0.041.06 million shs577,201 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+3.62%+11.15%+10.34%+2.50%+2,129.45%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-0.84%-0.21%+16.79%+21.31%+149.80%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.11%+15.70%+0.54%-14.69%+80.68%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+0.86%+3.64%-4.49%-7.33%+55.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$129.73
+2.6%
$118.06
$5.63
$148.83
$10.34B0.841.10 million shs1.08 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$77.15
+1.1%
$68.04
$30.02
$80.20
$9.60B0.382.21 million shs1.62 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.71
+3.9%
$23.00
$12.97
$27.72
$11.84B1.695.41 million shs8.28 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$29.28
-0.2%
$30.80
$19.26
$39.28
$2.57B-0.041.06 million shs577,201 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+3.62%+11.15%+10.34%+2.50%+2,129.45%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-0.84%-0.21%+16.79%+21.31%+149.80%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+5.11%+15.70%+0.54%-14.69%+80.68%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+0.86%+3.64%-4.49%-7.33%+55.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.93
Moderate Buy$137.155.72% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$99.3028.71% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2018.96% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.82
Moderate Buy$50.6973.11% Upside

Current Analyst Ratings Breakdown

Latest IDYA, ELAN, CYTK, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingMarket Outperform
5/26/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingMarket Outperform$131.00
5/22/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Reiterated RatingOverweight
5/18/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Initiated CoverageOutperformBuy$99.00
5/18/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UpgradeOutperformStrong-Buy
5/12/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOverweight$92.00 ➝ $97.00
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/11/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetBuy$136.00 ➝ $140.00
5/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOverweight$95.00 ➝ $105.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$105.82M90.72N/AN/A($6.64) per share-11.62
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.89B2.42$2.53 per share9.36$13.01 per share1.82
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$225.27M11.42N/AN/A$10.67 per share2.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-109.57%-74.33%N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.592.34-4.95%7.42%3.66%8/6/2026 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)

Latest IDYA, ELAN, CYTK, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/5/2026Q1 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million
5/5/2026Q1 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million
3/23/2026Q4 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.75
8.75
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
4.21
4.21
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
10.74
10.74

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6179.70 millionN/ANot Optionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.86 million83.73 millionOptionable

Recent News About These Companies

IDEAYA Biosciences Files New Shelf Registration Statement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$129.73 +3.32 (+2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$129.71 -0.02 (-0.02%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$77.15 +0.86 (+1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$77.26 +0.11 (+0.14%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.70 +0.89 (+3.88%)
Closing price 03:59 PM Eastern
Extended Trading
$23.10 -0.60 (-2.55%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$29.28 -0.07 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$29.26 -0.02 (-0.05%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.